Gilead's Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)
Stocks in this Quantisnow insightHealth Care
Historical context for GILD
Across the 22 sessions after earlier GILD headlines, the stock closed higher 12 times and lower 10 times, with a median move of 0.7% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | GILD | SPY |
|---|---|---|---|
| May 27, 2026 | Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead's Livdelzi (Seladelpar) | -0.0% | -0.0% |
| May 26, 2026 | FDA Approval for HEPCLUDEX issued to GILEAD SCIENCES INC | -0.5% | +0.7% |
| May 22, 2026 | FDA Grants Accelerated Approval to Gilead's Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)and 3 other headlines that session | +3.0% | +0.4% |
| May 21, 2026 | FDA Approval for BIKTARVY issued to GILEAD SCIENCES INCand 2 other headlines that session | -0.1% | +0.2% |
| May 20, 2026 | Gilead Sciences upgraded by Maxim Group with a new price target | +0.1% | +1.0% |
| May 15, 2026 | Gilead Prices $3 Billion of Senior Unsecured Notes | -1.9% | -1.2% |
Keep researching GILD
Quantisnow market dataNASDAQ
GILD
Gilead Sciences Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Listed since
- 1992
Get push alerts for GILD
Full GILD profile on Quantisnow Follow GILD and get a push notification the moment its next story breaks.